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Abstract
Background: Epileptic encephalopathies are a group of childhood epilepsies that display high phenotypic and
genetic heterogeneity. The recent, extensive use of next-generation sequencing has identified a large number of
genes in epileptic encephalopathies, including UBA5 in which biallelic mutations were first described as pathogenic
in 2016 (Colin E et al., Am J Hum Genet 99(3):695-703, 2016. Muona M et al., Am J Hum Genet 99(3):683-694, 2016).
UBA5 encodes an activating enzyme for a post-translational modification mechanism known as ufmylation, and is
the first gene from the ufmylation pathway that is linked to disease.
Case presentation: We sequenced the genomes of two sisters with early-onset epileptic encephalopathy along
with their unaffected parents in an attempt to find a genetic cause for their condition. The sisters, born in 2004 and
2006, presented with infantile spasms at six months of age, which later progressed to recurrent, treatment-resistant
seizures. We detected a compound heterozygous genotype in UBA5 in the sisters, a genotype not seen elsewhere
in an Icelandic reference set of 30,067 individuals nor in public databases. One of the mutations, c.684G > A, is a paternally
inherited exonic splicing mutation, occuring at the last nucleotide of exon 7 of UBA5. The mutation is predicted to disrupt
the splice site, resulting in loss-of-function of one allele of UBA5. The second mutation is a maternally inherited missense
mutation, p.Ala371Thr, previously reported as pathogenic when in compound heterozygosity with a loss-of-function
mutation in UBA5 and is believed to produce a hypomorphic allele. Supportive of this, we have identified three adult
Icelanders homozygous for the p.Ala371Thr mutation who show no signs of neurological disease.
Conclusions: We describe compound heterozygous mutations in the UBA5 gene in two sisters with early-onset epileptic
encephalopathy. To our knowledge, this is the first description of mutations in UBA5 since the initial discovery that
pathogenic biallelic variants in the gene cause early-onset epileptic encephalopathy. We further provide confirmatory
evidence that p.Ala371Thr is a hypomorphic mutation, by presenting three adult homozygotes who show no signs of
neurological disease.
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Background
Epileptic encephalopathies are a group of childhood epilep-
sies characterized by severe seizures or other paroxysmal
electrical activities that contribute to impaired cerebral
function [1]. Several causes of epileptic encephalopathies
have been described, including cerebral structural abnor-
malities, inborn errors of metabolism, chromosomal anom-
alies, and single-gene mutations [1]. A large number of
single-gene mutations causing epileptic encephalopathies
have been identified through the recent, extensive use of
next-generation sequencing [1]. Currently, over 65 genes
are known in the early-onset epileptic encephalopathies, of
which 20 were discovered in the last three years alone [1, 2].
Here, we describe compound heterozygous mutations
in the recently identified epileptic encephalopathy gene,
UBA5, in two sisters with early-onset epileptic encephal-
opathy. To our knowledge, this is the first case of bialle-
lic mutations in UBA5 to be described since the initial
reports of pathogenic biallelic variants in UBA5 causing
early-onset epileptic encephalopathy [3, 4]. In addition,
we present three adult Icelanders homozygous for one
of the mutations detected in the sisters, p.Ala371Thr.
The three homozygous individuals show no signs of
neurological disease, which confirms that p.Ala371Thr is
acting as a hypomorphic mutation.
Case presentation
The two affected sisters were born in 2004 (II-2) and 2006
(II-3) (see pedigree, Fig. 1). Their father (I-1; American,
white non-Hispanic, born in 1975), mother (I-2; Icelandic,
born in 1977) and two brothers (II-1; born in 2002 and II-
4; born in 2014) are unaffected. The pregnancies were un-
eventful, both sisters were delivered full term with normal
birth weight. They first became symptomatic at three
months of age, showing failure to thrive and a decline in
motor skills such as tracking and head support. The older
sister (II-2) was admitted to the Children’s Hospital of
Iceland at six months of age because of increasing irrit-
ability, nutritional difficulties and episodes of infantile
spasms. An electroencephalogram, performed at the time,
showed modified hypsarrhythmia. Her seizures initially
responded to vigabatrin, the infantile spasms disappeared
and she became less irritable. After a few weeks however,
the infantile spasms returned and she responded only
partly to high doses of adrenocorticotropin. She developed
severe intellectual disability with seizures and dystonic
cerebral palsy and was diagnosed with early-onset epilep-
tic encephalopathy.
The younger sister (II-3) had a similar clinical course, al-
though slightly milder. She has severe intellectual disability,
epilepsy, and quadriplegic cerebral palsy with extrapyramidal
features, and received the same diagnosis as her sister of
early-onset epileptic encephalopathy. A clinical examination
of the two sisters, at ages 10 and 8, showed mild dysmorphic
facial features, including a slightly upturned nose and mild
hypertelorism, difficulties with visual fixation and following,
and low muscle tone (although normal muscle strength
proximally and distally). Opthalmologic examinations
showed no abnormalities of the retina or optic nerves and
normal reactions to strong light, bilaterally. An MRI, per-
formed at ages 12 and 10, showed relatively wide sulci and
mild cerebral atrophy (Additional file 1: Figure S1). At their
latest examination, both sisters still had frequent seizures.
They have shown limited response to several antiepileptic
drugs in high doses (including high dose phenytoin, leveti-
racetam, and high dose vigabatrin). The CARE guidelines
were followed in this case description.
In an attempt to find a genetic cause for their condition,
we sequenced the genomes of the two sisters and their par-
ents to a targeted depth of 30× (for a detailed description of
the whole-genome sequencing see Additional file 2: Supple-
mentary methods). The genetic analysis focused on rare ge-
notypes at coding and splicing regions in the genome (SNPs
and small indels). Large-scale sequencing of the Icelandic
population by deCODE genetics [5, 6] has yielded a local
normative set, currently consisting of 30,067 whole-genome
sequenced Icelanders (to a median depth of over 30×). The
minor allele frequency of sequence variants was determined
from this set of whole-genome sequenced Icelanders as well
as from an international dataset of 138,632 individuals either
whole-exome or whole-genome sequenced (the genome
Aggregation Database, gnomAD [7]). We defined rare auto-
somal recessive genotypes as homozygous or compound
Fig. 1 Pedigree of the two affected sisters. Family members are
represented by their birth years. The affection status of the sisters is
indicated by filled symbols. The status of the two UBA5 (NM_024818.3)
mutations is provided below each family member, where red refers to
the status of the missense mutation, p.Ala371Thr (m1), blue refers to
the status of the exonic splicing mutation, c.684G > A (m2), and the
plus sign (+) refers to the wild-type allele
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heterozygous sequence variants, each with a minor allele
frequency lower than 2% in our set and in gnomAD. We
defined rare autosomal dominant genotypes as variants with
a minor allele frequency lower than 0.1% in our set and gno-
mAD. We assessed all possible modes of inheritance but
considered a recessive mode of inheritance or a dominant
mode of inheritance with parental germline/somatic mosai-
cism most likely, based on the manifestation of two affected
siblings. Due to the extent of clinical similarity and the
severity of their condition, we focused on genotypes shared
by the two sisters.
We identified two rare genotypes that fulfilled the above
criteria (Additional file 3: Figure S2 shows our approach to
variant filtering). One of the genotypes was in MTA1, a
gene not previously known to contribute to Mendelian
disease (Additional file 3: Figure S2). The other was a
compound heterozygous genotype in UBA5, a gene that
has only very recently been linked to an epilepsy phenotype
[3, 4, 8] (Early Infantile Epileptic Encephalopathy 44,
EIEE44, MIM: 617,132, Creation date: 09/27/2016). UBA5
encodes ubiquitin-like modifier activating enzyme 5, a ne-
cessary component of a post-translational modification
mechanism known as ufmylation [4]. Compound heterozy-
gous mutations were first reported in UBA5 in two Chinese
siblings presenting with autosomal recessive cerebellar
ataxia in February 2016 [8]. In September 2016, two reports
describing the pathogenic role of UBA5 biallelic variants in
early-onset epileptic encephalopathy were published [3, 4].
We would like to point to high similarity between the two
affected sisters in Iceland and the cases presented in these
two reports [3, 4] (Table 1).
The compound heterozygous genotype we detected con-
sists of a paternal exonic splicing mutation, c.684G > A,
and a maternal missense mutation, p.Ala371Thr, in UBA5
(Table 2 and Fig. 1). Sanger sequencing confirmed the
genotypes of the sisters and their parents. The two un-
affected brothers (II-1 and II-4, Fig. 1 and Additional file 4:
Table S1) were Sanger genotyped and each found to be
heterozygous for only one of the mutations.
The paternally inherited mutation, c.684G > A, is a splice
region mutation occurring at the last nucleotide of exon 7
of UBA5 in the exonic part of the splice donor (5′) region
(Additional file 5: Figure S3). It appears to be a very rare
and recent mutation, absent from 30,067 whole-genome se-
quenced Icelanders and detected only once in gnomAD’s
set of 138,632 whole-exome/genome sequenced individuals
[7]. The mutation affects a highly conserved nucleotide,
both in terms of evolutionary conservation (Table 1) and
with regards to the consensus sequence for human splice
donor regions. Based on both the high conservation of this
position and a predicted altered splicing motif (in silico pre-
dictions) we suggest that the mutation disrupts the donor
splice site of exon 7 of UBA5. Two possible scenarios can
result from this disruption; A) skipping of the subsequent
exon in UBA5 (exon 8) or multiple exons (exons 8–12)
from the mature mRNA or B) a read-through into intron 7
Table 1 Clinical features of the two affected sisters compared to reported phenotypes in cases of UBA5 early-onset epileptic
encephalopathy
Affected sisters UBA5 early-onset epileptic encephalopathy cases [2, 3]
Pregnancy and delivery Normal Normal
Failure to thrive Yes Yes
Central
Nervous
System
Early-onset epileptic encephalopathy
Dystonic cerebral palsy
Hypotonia
Infantile spasms
Seizures:
- Recurrent
- Resistant to treatment
Developmental delay
Decline in motor skills
Early-onset epileptic encephalopathy
Dystonic movements
Spasticity
Hypotonia
Infantile spasms
Seizures:
- Recurrent
- Pharmaco-resistant
Developmental delay
Decline in motor skills
Intellectual disability Severe Ranging from moderate to severe
Optic fundi Normal Normal
Vision Difficulty in fixating and following Impaired fixation, squinting
Microcephaly Yes Yes (< −3SD), one case with -2SD
Brain MRI Relatively wide sulci
Mild cerebral atrophy
Widening of sylvian fissures (lateral sulcus)
Thin corpus callosum
White matter hyperintensities
Delayed myelination
Mild cerebellar hypoplasia
Mild cortical and central atrophy
Mild cerebral/cerebellar atrophy
EEG abnormalities Modified hypsarrhythmia Ranging from none to hypsarrhythmia
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of UBA5 with the introduction of a premature stop codon
18 amino acids downstream of the exon/intron boundary
of exon 7. Both scenarios would result in nonsense-
mediated decay of the mature transcript with a correspond-
ing loss-of-function effect. We note that in one of the
UBA5 families described previously (by Muona et al.) a
UBA5 mutation was detected at the third nucleotide of the
acceptor (3′) end of exon 2 [4]. That mutation was initially
annotated as a missense, p.Arg55His, but was reclassified
as a loss-of-function (LoF) mutation when shown to
interfere with splicing and result in nonsense-mediated
decay [4].
The other mutation detected in UBA5 in the two sisters
is a missense mutation, p.Ala371Thr, inherited from their
mother. The mutation has a minor allele frequency of
0.38% in Iceland, 0.58% in Finnish and 0.25% in non-
Finnish Europeans, with lower frequencies in other popu-
lations [7]. The two reports describing the role of biallelic
variants in UBA5 in early-onset epileptic encephalopathy
classify p.Ala371Thr as a hypomorphic allele that contrib-
utes to a severe neurological phenotype only when in
trans with a LoF in UBA5 [3, 4]. In our set of 150,656
chip-genotyped Icelanders, into which we have imputed
all variants detected in a large set of whole-genome se-
quenced Icelanders [5], we have identified three individ-
uals who are homozygous for the p.Ala371Thr mutation.
We have extensive phenotypic information linked to the
set of 150,656 genotyped individuals. All three individuals
homozygous for p.Ala371Thr have reached adult age
without showing signs of a neurological phenotype, and
two of them have three and six children, respectively
(Table 3). Our findings confirm the hypomorphic nature
of p.Ala371Thr and prove that it is only pathogenic when
in combination with a LoF in UBA5.
Discussion and conclusions
We describe a compound heterozygous genotype in UBA5
in two sisters with early-onset epileptic encephalopathy.
The sisters and their parents were initially whole-exome
sequenced in 2013. The two compound heterozygous
mutations in UBA5 were detected in the whole-exome data
but at the time, no disease-causing mutation had been
described in this gene and the genotype was therefore not
read as a pathogenic one. We decided to repeat the analysis
of the family using whole-genome sequencing in 2016. In
September 2016 the two reports [3, 4] on biallelic variants
Table 2 Annotation of the two UBA5 mutations detected in the sisters
mutation A (maternal) mutation B (paternal)
Position (GRCh38) chr3:132,675,903 chr3:132,671,881
Variant consequence Missense Splice region (donor site) leading to a LoF
Variant genotype Heterozygous Heterozygous
cDNA changea c.1111G > A (NM_024818.3) c.684G > A (NM_024818.3)
Protein changea p.Ala371Thr (NP_079094.1) p.(Ala228=) (NP_079094.1)
Transcript length 404 AA (NM_024818.3) 404 AA (NM_024818.3)
Exon/exons in transcript 11/12 (NM_024818.3) 7/12 (NM_024818.3)
Allelic frequency Iceland 0.38% (249/30,067 Icelanders) Absent from 30,064 Icelanders
Allelic frequency abroad (gnomAD [7]) 0.58% (75/12,985 Finnish individuals)
0.25% (157/62,175 European,
non-Finnish individuals)b
Seen in one individual (European, non-Finnish)
out of 138,632
SIFTc Deleterious NA
PolyPhen-2c Possibly damaging NA
GERP conservation scored Highly conserved (5.44) Highly conserved (4.95)
Disease in literature Early Infantile Epileptic Encephalopathy-44 [2–4]
aFunctional annotation as suggested by the Human Genome Variation Society (HGVS)
bA lower frequency in other populations
cSIFT and PolyPhen-2 are scores for the predicted effect of amino acid substitution on protein structure and function
dThe Genomic Evolutionary Rate Profiling (GERP) framework gives a measure of evolutionary conservation based on the alignment of sequences from 29
mammalian species
Table 3 Icelandic individuals homozygous for p.Ala371Thr in UBA5
Individual Gender Year of birth Number of
offspring
Main reported
phenotypes
A Female 1934- 3 Coronary artery disease
Essential hypertension
Osteoarthritis
B Male 1946- 0 Myocardial infarction
C Female 1940- 6 Coronary artery disease
Ulcerative colitis
For the three p.Ala371Thr homozygous individuals detected in the Icelandic
reference cohort we show gender, year of birth, number of offspring and main
clinical phenotypes. The phenotypes were obtained from the National
University Hospital of Iceland’s registry. All three individuals are still alive and
two of them have children, none of them has a reported neurological
condition. Individuals B and C are siblings
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in UBA5 causing early-onset epileptic encephalopathy were
published, allowing us to conclude on the pathogenicity of
the compound heterozygous mutations in UBA5 in the two
affected sisters. The progression of this case underlines the
importance of periodically revisiting the most recent litera-
ture when performing genetic analysis of clinical cases.
We have identified three adult and unaffected individuals
homozygous for one of the mutations detected in the two
sisters, p.Ala371Thr, thus confirming that it is hypomorphic
and not disease-causing by itself. As we do, the authors of
the two reports on biallelic variants in UBA5 describe the
combination of p.Ala371Thr and a loss-of-function muta-
tion to cause early-onset epileptic encephalopathy [3, 4].
The paternally inherited exonic splicing mutation we
present is predicted to result in abnormal splicing of UBA5
with a subsequent loss-of-function effect.
UBA5 is the first ufmylation gene identified in epileptic
encephalopathies. Although a link between defects in other
post-translational modification mechanisms and this
disease group has been demonstrated [9], the exact role of
impaired ufmylation in epileptic encephalopathy is still un-
clear. The identification and reporting of new pathogenic
UBA5 genotypes adds necessary evidence to the pathogen-
etic story of UBA5 and defects in the ufmylation process.
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